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Synthetic strategies to combat antibiotic resistance 
By 
Jonathan Fifer 
University of New Hampshire, December 2018 
 
The design and synthesis of β-lactamase inhibitors is a constant area of study to overcome 
the growing problem of resistance to β-lactam antibiotics.  Serine dependent β-lactamase enzymes, 
through a hydrolysis mechanism, can deactivate many traditional β-lactam antibiotics.  Designing 
drugs to specifically target β-lactamases is of great interest because such drugs could be used in 
tandem with traditional β-lactam antibiotics.  Aza-β-lactam molecules have been theorized to be 
less vulnerable to hydrolysis than the traditional β-lactams.  Nucleophilic attack of the active-site 
serine of the β-lactamase on the aza-β-lactam ring would lead to a carbamoyl-enzyme intermediate, 
which would be partially stabilized due to the neighboring nitrogen atom and thus is expected to 
be more hydrolytically stable than the corresponding acyl-enzyme intermediate of a β-lactam. 
 The initial attempt to synthesize the aza-carbacepham 1 utilized a rhodium catalyzed N-H 
insertion as the key step to form the substituted piperidine ring fused to the aza-β-lactam ring.  
With the use of aldehyde 8, a Wittig reaction was conducted to extend the carbon chain, but 
problems arose with the removal of the N-acetyl group.  Multiple pathways were attempted but all 
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were unsuccessful in cleaving the N-acetyl group, so a different synthetic approach was explored 
that utilized an aldol reaction to form the respective ring. 
 The synthesis of aza-carbapenam 33 originally proceeded via enol-ether 34a/b followed 
by acid catalyzed conversion to the corresponding alcohol 35.  But due to low yields, a different 
approach involving hydroboration of alkene 47 was explored.  With the use of a model system, the 
Wittig conditions were optimized and applied to aldehyde 8 to form alkene 47.  Traditional 
hydroboration conditions were then attempted with the formation of unexpected product 48. 
 Rapamycin has been found to potentiate oxacillin activity against several strains of 
methicillin-resistant Staphylococcus aureus (MRSA), but its mechanism of action is unknown.  
The interaction of rapamycin with oxacillin and MRSA are going to be studied with a photoaffinity 
labeling process.  Diazirine linker 49 was synthesized and initial steps to alkylate rapamycin were 







 The β-lactam antibiotic penicillin was discovered in 1928 by Alexander Fleming.1  The  
full potential of penicillin was not understood until the 1940s, when the era of antibiotics truly 
began as the demand for medication increased drastically.  With the demand for large-scale 
production due to World War II, penicillin became one of the first antibiotics on the market.2  The 
effectiveness of penicillin then brought on the discovery of other compounds that had similar 
bacterial properties.  Chemists were eager to apply the antibiotic properties of the β-lactam ring of 
penicillin and began extensively researching natural product isolation and synthesis.  The β-lactam 
nucleus, 6-aminopenicillanic acid,  was discovered to be crucial when synthesizing and modifying 
penicillin.3  Cephalosporin C was isolated from a strain of Cephalosporium acremonium,  and this 
brought on an entirely new family in the β-lactams.3  The β-lactam family includes penicillins, 
cephalosporins, carbapenems, and monobactams represented below in Figure 1.4 
 
Figure 1.  The four common classes of β-lactam antibiotics used in the clinic. 
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The β-lactams have been a powerful tool as a treatment for bacterial infections leading 
them to become a commonly prescribed class of antibiotics.  The antibacterial property comes 
from the peptide mimic; penicillin mimics a component of the cell wall which allows it to bind to 
an enzyme that constructs and strengthens the cell wall.5,6  A penicillin-derived entity is 
irreversibly bound by the transpeptidase and carboxypeptidase enzymes essential for bacterial cell 
wall synthesis.  These biosynthetic enzymes are obvious therapeutic targets leading to inhibition 
of the peptidoglycan cross-linking transpeptidase that cleaves the peptidoglycan D-Ala-D-Ala 
terminus in the serine acylation half-reaction.5,6  With loss of the terminal D-Ala, a cross-link is 
formed in the deacylation half-reaction.  Should this enzyme bind a substrate mimic, the initial 
acylation reaction remains unaffected, but the deacylation mechanism is abolished, the enzyme 
will fail to complete cell wall synthesis.5,6 
With the synthesis halted, the cell wall loses its integrity leading to bacterial cell death.5,6  
The crystal structures of these enzymes have been studied to identify the enzyme active sites and 
determine which interactions are essential to the high binding affinity of β-lactam antibiotics.7  
Due to extensive overuse and misuse, bacteria have developed mechanisms of defense against the 
β-lactam antibiotics.  Only a few years after penicillin was used clinically, reports of penicillin-
resistant Staphylococcus aureus emerged.8  This was mainly due to the expression of β-lactamase 
enzymes.  These enzymes hydrolyze the β-lactam ring eliminating the drug’s antibacterial activity.   
The β-lactamase enzymes are divided into classes A, B, C, and D.  Classes A, C, and D 
utilize an active site serine to initiate β-lactam hydrolysis (Scheme 1).9  Each follow a similar 
mechanism of hydrolysis, but differ in the catalytic residue to hydrolyzes the β-lactam ring.  Class 
C utilizes a lysine-tyrosine pair for the catalytic residue, compared with class D, which is activated 





Scheme 1.  The hydrolysis of a β-lactam by a serine-β-lactamase. 
With class D, a serine nucleophile attacks the lactam carbonyl yielding a covalent acyl-
enzyme intermediate.  The tetrahedral oxyanion intermediate for this acylation reaction is 
stabilized by two main-chain amides and electrostatically by a second active-site lysine. The ester 
linkage is then hydrolyzed by attack of the α face of the ester by an active-site water affording an 
inactivated β-lactam.11  Much progress has been made in attempts to prevent the hydrolysis of the 
acyl-enzyme intermediate, but more distinct enzyme types continue to be discovered.  As of 2017, 
the Comprehensive Antibiotic Resistance Database (CARD) lists over 1200 different serine-β-
lactamase enzymes.12   
Class B β-lactamases employ one or two Zn2+ ions to hydrolyze the β-lactam antibiotic 
(Scheme 2).13  The role of the Zn2+ ions is to catalytically activate the hydrolytic water to open the 
β-lactam ring, and simultaneously stabilize the reaction intermediates.14  Metallo-β-lactamases 
have been viewed as less of a threat due to their more geographically localized outbreaks of the 
enzyme, but the enzyme’s molecular epidemiology is changing.13  This change is driven by the 
emergence of mobile genetic elements containing metallo-β-lactamase genes that are now 
frequently found in Gram-negative pathogens including Enterobacteriaceae, Pseudomonas, and 





Scheme 2.  Mechanism of metallo-β-lactamase catalyzed hydrolysis of β-lactam antibiotic. 
In 1959 various penicillin analogues such as methicillin were developed in attempts to 
sterically protect the β-lactam ring.17  Shortly after methicillin was brought to the market, 
methicillin-resistant Staphylococcus aureus (MRSA) isolates were detected.18  The increased 
resistance to methicillin was due to alterations of the β-lactamase enzyme that resulted in a lower 
affinity for the β-lactam.19  The restriction to the active site made treatment of the bacteria difficult, 
and the growing emergence of MRSA identified a need for new treatment options.   
Cephalosporins were discovered in the late 1940s, and were found to be less susceptible to 
deactivation by staphylococcal β-lactamase.8  Early variations of cephalosporins were found to be 
active against staphylococci, but were found to be even more beneficial against gram-negative 
organisms such as Pseudomonas aeruginosa.17  Carbapenems and monobactams, discovered in 
1985, were found to be useful against bacteria typically unaffected by other β-lactam.20  
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Carbapenems have been reserved for treatment of the most difficult bacterial infections, however,  
resistance to them has become more widespread due to the increased prevalence of 
carbapenemases.8  Carbapenemases represent the most versatile family of β-lactamases, with an 
extensive spectrum of β-lactam-hydrolyzing enzymes. Although known as “carbapenemases,” 
many of these enzymes recognize almost all hydrolyzable β-lactams, and most are resilient against 
inhibition by many commercially available β-lactamase inhibitors.21 
The current methods to combat β-lactam resistance include: designing new β-lactam 
antibiotics that are less susceptible to hydrolysis, or designing new β-lactamase inhibitors to 
prevent β-lactam hydrolysis.8   Designing new β-lactam antibiotics is an ongoing process, but the 
production of β-lactamase inhibitors has been more successful.  In 1972 clavulanic acid was found 
to have limited antibiotic activity despite the β-lactam ring (Figure 2), however it shows a high 
affinity for β-lactamase enzymes.22  In 1984, Augmentin, which contains clavulanic acid and 
amoxicillin, became the first β-lactam/β-lactamase inhibitor antibiotic and in 2001 Augmentin 
became the best-selling antibiotic on the market.8 
With much work being done to find potential inhibitors of β-lactamases, 
diazabicyclooctanes have shown promising results.23  Mimics of β-lactams, such as Avibactam 
(Figure 2), have been found to have activity against class A, C, and D β-lactamase.24    This is due 
to the unique carbamoyl acyl-enzyme intermediate that does not decompose by a hydrolytic 
mechanism.25  In its place, the decarbamylation occurs by a recyclization of the 





Figure 2.  Structure of Avibactam and Clavulanic acid. 
Bicyclic imidazolidinones represented in Figure 3, are found to also have interesting 
inhibition ability.26  When tested, low antimicrobial activity was observed against bacteria for 
imidazolidinones A, B, C, and D from figure 3.26,27   
 
Figure 3.  Examples of β-lactam mimics with a bicyclic imidazolidinone framework. 
Chandrakala et al. explored a synthetic route to make 1,3-diazetidin-2-ones (aza-β-lactams) 
and proposed that the aza-β-lactam could theoretically have high inhibition ability against β-
lactamases.26  The process begins with the nucleophilic attack of the serine β-lactamase on the 
non-traditional β-lactam ring, which leads to a carbamoyl-enzyme intermediate that is partially 
stabilized due to the neighboring nitrogen atom.  The carbamate acyl-enzyme intermediate is 
expected to be more hydrolytically stable than the corresponding ester acyl-enzyme intermediate 




Scheme 3.  Resonance stabilization of the acyl-enzyme intermediate of an aza-β-lactam with a β-
lactamase compared to a traditional β-lactam with a β-lactamase. 
In the more traditional β-lactam structure, extra stabilization is not present because the 
enzyme attacks the β-lactam ring and forms a corresponding ester that can readily be hydrolyzed 
to leave the β-lactam deactivated.  With growing resistance due to serine-β-lactamases and 
metallo-β-lactamases, new treatment options are of great interest. The aza-β-lactam analogues are 
close structural mimics of β-lactams and also benefit from resonance stabilization in the acyl-
enzyme intermediate.  Aza-β-lactam structures have not been examined for activity against β-
lactamases, so an efficient synthetic route is required to synthesize a library of derivatives. 




-Results and Discussion- 
 The Johnson research group at University of New Hampshire conducted computational 
studies to determine whether or not several different acyl-enzyme intermediates were less 
susceptible to hydrolysis than an ester.28  The C6 position of the β-lactam was substituted with 
different heteroatoms, which would form an acyl-enzyme ring linkage.28  The C6 position was 
substituted with nitrogen, oxygen, and a sulfur to study the different strengths of the respective 
acyl-enzyme intermediate (Figure 4).   
 
Figure 4.  Structures explored computationally for the relative strength of the acyl-enzyme 
linkage. 
 The potential energy surface of the methanol-assisted hydrolysis of the acyl-enzyme 
intermediate was compared for each substituted variation.  Based on the computational results, all 
derivatives have a carbamate acyl-enzyme linkage that is less susceptible to hydrolysis compared 
to the ester of the typical β-lactam (X= CH2), except for the oxalactam derivative.28  The data also 
suggest that the N-acetyl aza-β-lactam would be the most reasonable to form acyl-enzyme 
intermediate that is less susceptible to the methanol-assisted hydrolysis.28  With promising 
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computational data, investigation to efficiently synthesize various aza-β-lactam derivatives was 
explored.  
In order to test the aza-β-lactam compounds for inhibitory activity against β-lactamases, a 
simple and efficient synthetic pathway is needed.  Ideally the pathway would utilize the same 
chemistry but have minor variations to produce multiple derivatives.  The first compound of 
interest was an aza-carbacepham (Figure 5, 1).  After a general synthetic pathway is determined, 
the phenyl ring will be functionalized with an electron withdrawing or donating group.  Due to the 
conjugation of the structure, the addition of select groups could change the electronics of the aza-
β-lactam ring, which may affect the acylation or deacylation rates during the reaction with β-
lactamases. 
The initial pathway utilized a rhodium-catalyzed N-H insertion for the formation of the 
respective ring attached to the aza-β-lactam ring (Scheme 4).29  The proposed method would 
require minimal steps that utilized mild reaction conditions to efficiently synthesize aza-
carbacepham 1 in Figure 5.   
 
Figure 5.  The target molecules of the aza-carbacepham 1-4. 
 The synthetic pathway  began with the formation of pyrimidin-2-one 6 from phenyl urea 5 
and acetylacetone.30  Compound 6 was then exposed to photochemical conditions to form the 




Scheme 4.  Initial synthetic steps to form aza-carbacepham 1 utilizing a Rh catalyzed N-H 
insertion. 
 To combat the low yield, flow chemistry was used to optimize the photochemical 4π 
electrocyclization.  Flow chemistry is useful to the synthetic chemist because of such advantages 
as reduced reaction times, increased heat management, increased product purity and atom 
efficiency.31  The high surface-to-volume ratio allows for more efficient mixing and photoreactive 
conversion, and the use of automated systems allow continuous production of compounds with 
high efficiency.  For the photochemical 4π electrocyclization of 6 to 7, the initial concern with the 
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photochemical reaction was the heat generated by the photoreactor, which from long reaction times 
might promote the reverse reaction.  A simple photo-flow-reactor was constructed in attempts to 
minimize this issue.  Polytetrafluoroethylene (PTFE) tubing was coiled around a large glass tube 
that had the ability to be cooled.  The reaction mixture could then flow through the coil with the 
use of a syringe pump.  With this design, various flow rates could be used to allow for longer 
reaction times and still minimize the heat generated in the solution.  The reaction was monitored 
by 1H NMR, and the conversion ratio of starting material 6 to product 7 was observed (Table 1).   
 The flow rate was varied to determine how the reaction times affect the percent conversion 
(Table 1).  By decreasing the flow rate and thus increasing the reaction time, the starting material 
is given more exposure to the radiated light, which increases the efficiency of the reaction.  
Decreasing the flow rate from 0.322 mL/min (30 minutes) to 0.161 mL/min (60 minutes) results 
in a large increase in product formation.  Varying the concentration was next investigated.  The 
original concentration of 0.016 M was increased to 0.032 M and 0.048 M; with the increase in 
concentration, a decrease in product formation was observed (Table 1).  This is likely due to the 
low solubility of 6 in benzene.  The syringe pump had a difficult time pushing the solution through 
the reactor.  As the solution was pushed through the photo-reactor, solid would form on the syringe 


















of 6 to 7 
0.016 30 0.322 0 21 
0.016 60 0.161 0 44 
0.032 30 0.322 0 23 
0.032 60 0.161 0 36 
0.048 30 0.322 0 15 
0048 60 0.161 0 32 
0.016 30 0.322 rt 33 
0.016 120 0.080 rt 92 
0.016 150 0.060 rt 95 
 
Cooling the reaction mixture was examined to determine if it was necessary.  When the 
reaction was conducted at room temperature, an increase in the conversion of 6 to 7 from 21% to 
33% was observed.  Nishio et al., also reported that longer reaction times dramatically increase 
the overall conversion of pyrimidin-2-one to the corresponding diazabicyclo-ene.32  Much slower 
flow rates were used, 0.080 mL/min (120 min) and 0.060 mL/min (150 min), to yield 92% and 
95% conversion, respectively.  Unfortunately, with large scale reaction mixtures and long reaction 
times, a side product was observed by thin-layer chromatography (TLC).  Due to the alkene on the 
newly formed ring, an additional cyclization occurred causing an oligomer to form when examined 
my NMR.  The formation of the oligomer decreased the isolated yield of 7, but the increase from 
20% to 68% is a respectable gain in yield.   
The oxidative cleavage of alkene 7 to form the corresponding aldehyde 8 was first explored 
using a modified procedure from Inoue et al.33,34  Osmium tetroxide (OsO4) was used in a 1:1 
stoichiometric ratio to convert the alkene to a diol, which could be converted to the respective 
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aldehyde with the use of sodium periodate (NaIO4), (Scheme 5).  When this was attempted with 
7, no product formation was observed.33  In a different attempt, OsO4 was used catalytically with 
N-methylmorpholine N-oxide (NMO) as co-oxidant (Scheme 5).34  Unfortunately, no product 
formation was observed again.  It was hypothesized that the second nitrogen atom adjacent to the 
alkene may interfere with the reaction outcome, so a more direct approach was examined.  
Compound 7 was subjected to ozonolysis and a reductive workup with dimethyl sulfide to form 
aldehyde 8 in 60% yield.26   
 
Scheme 5.  Oxidative cleavage of 7 with OsO4 and NaIO4 to form aldehyde 8. 
With the formation of aldehyde 8, a Wittig reaction was used to extend the carbon chain to 
the required length for later cyclization.  Phosphonium salt 9 was easily synthesized in one step by 
reacting triphenylphosphine with ethyl-4-bromobutyrate.35  Phosphonium salt 9 was deprotonated 
in situ with NaHMDS, and the resulting phosphorane was allowed to react with 8 to form 10.26,35  
The low yield was due to a difficult isolation; multiple attempts afforded only a small amount of 
pure product 10.  The Wittig product 10 was easily hydrogenated with Pd/C to form 11.26  
Regrettably, this brought up an issue with the current synthetic pathway; the N-acetyl group needed 
to be removed without reducing the ester on the end of the carbon chain. 
Various reducing techniques were explored in an attempt to selectively remove the N-
acetyl group.  The first approach utilized the Corey-Chaykovsky reaction conditions (Scheme 4).36  
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Under these conditions, a sulfur ylide is typically formed that can convert carbonyl compounds 
such as ketones to their corresponding epoxides.  Chandrakala et al. observed that when Me3SI is 
used to convert aldehyde 8 to an epoxide, simultaneous cleavage of the N-acetyl group occurs.26  
When 11 was subjected to these conditions, removal of the N-acetyl group was not observed.  A 
modified procedure from Alessandro et al. was attempted, which utilized n-BuLi in THF for more 
efficient generation of the sulfur ylide.37  Even under these conditions, removal of the N-acetyl 
was not observed.   Aldehyde 8 was also subjected to the Corey-Chaykovsky conditions in attempts 
to reproduce the work of Chandrakala et al.; interestly no epoxide formation was observed.    
Other reducing agents were also explored to remove the N-acetyl group from compound 
11 (Scheme 6), lithium tri-tert-butoxyaluminum hydride and borane tetrahydrofuran complex were 
found to be unsuccessful.38  A new strategy was examined: removal of the acetyl group before the 
carbon chain is extended.   
 
Scheme 6.  Different reductive methods explored to remove N-acetyl group. 
Chandrakala et al. observed that a strong reducing agent such as LiAlH4 is able to reduce 
the aldehyde to the alcohol and simultaneously cleave the N-acetyl group.26  More mild reducing 
agents, such as NaBH4, reduced the corresponding aldehyde but do not remove the N-acetyl.
26   
With a modified procedure from Dess et al.,  a DMP oxidation was attempted to oxidize alcohol 
16 to aldehyde 17 (Scheme 7).39  Aldehyde 8 was reduced with LiAlH4 to form alcohol 16, this 
was then subjected a DMP oxidation in attempt to form 17. NMR analysis of the crude sample 
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indicated a small amount of aldehyde formation, but it was unable to be isolated.  Another common 
oxidizing agent , PCC,  was used but unfortunately no product formation was observed by TLC, 
the hindered environment of the alcohol could have prevented the reaction from occurring.26  With 
removal of the N-acetyl group being problematic and the Wittig reaction of 10 being very low 
yielding, a different synthetic strategy was explored.  The new route used an N-alkylated aldol ring 
closure to form aza-carbacepham 1 (Scheme 8).26   
 
Scheme 7.  Early removal of N-acetyl with LiAlH4 prior to Wittig reaction. 
Treatment of aldehyde 8 with the phosphorane derived from 
(carbethoxymethyl)triphenylphosphonium bromide formed the Wittig product 18, which was 
followed by catalytic  hydrogenation of the alkene to produce 19.26,40  LiAlH4 was used to reduce 
the ester to the corresponding alcohol 20 and concurrently cleave the N-acetyl group.26,40  The 
initial isolated yield was low, therefore the reaction was then cooled to -10 οC in attempt to slow 
down the rate and diminish the harshness of the reaction conditions.  Cooling the reaction more 
showed a slight increase in yield.  The molar equivalents were also reduced from a 3:1 to 1:1 ratio 
of LiAlH4 to 19, the corresponding yield was increased to 49%.  
A tert-butyldimethylsilyl (TBDMS) protecting group was selected for its ability to 
withstand basic conditions.  tert-Butyldimethylsilyl chloride (TBDMSCl) was used to protect the 
primary alcohol of 20 to yield TBDMS ether 21.26,40  The primary alcohol was protected to allow 
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for the nitrogen atom to be alkylated.  NaH was used to deprotonate the N-H, which was followed 
by the addition of ethyl bromoacetate to yield N-alkylated TBDMS ether 22.26,40   
 
Scheme 8.  New synthetic pathway to reach aza-carbacepham 1 through a N-alkylated Aldol ring 
closure. 
The deprotection of 22 was attempted with tetra-n-butylammonium fluoride (Bu4NF) and 
was found to be low yielding.26,40  The initial attempt at the deprotection gave alcohol 23 in a 62% 
yield.26,40  Unfortunately, scaling up the reaction diminished the yield to <10%.  It was observed 
17 
 
that the compounds in the reaction undergo degradation when the stoichiometric ratio of Bu4NF 
to 22 is high.  The initial attempt used a 2:1 ratio of Bu4NF to 22, and after 30 min one additional 
equivalent of Bu4NF was added until all of 22 was consumed.  In attempts to diminish degradation, 
the molar equivalents were dropped to a 1:1 ratio. Unfortunately, lowering the molar equivalents 
lengthened the reaction time, 1 h to 3 h, before the disappearance of starting material was observed.  
After purification, very little alcohol 23 was isolated.   In attempts to slow down degradation, the 
solution was cooled to -10 οC.  The reduced temperatures resulted in decreased degradation, but 
the reaction yield was still very low. 
Karimi et al. reported that N-iodosuccinimide (NIS) in methanol is a gentle and efficient 
means to remove TBDMS protecting groups with subsequent easy purification.41  When this was 
attempted with TBDMS ether 22, the reaction was monitored by TLC and no change was observed 
(Scheme 9).  Karimi et al. used simple alkyl chains with minimal functional groups for the study.  
The various functional groups of 22 could have prevented any reaction from occurring.   
 
Scheme 9.  Attempted TBDMS removal with NIS. 
 The small quantity of alcohol 23 obtained was nonetheless carried through the pathway to 
synthesize the final compound.  The primary alcohol was oxidized to the corresponding aldehyde 
with the use of PCC to form aldehyde 24.26  With the use of NaH, an aldol cyclization was used to 
form 25.26  With the formation of 25, the final deprotection to convert the ethyl ester to the 
corresponding acid was next explored.  25 was not used due to the small amount recovered from 
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purification, ~2 mg.  Instead 18 was used due to the convenience of synthesizing the compound in 
minimal steps.   
Two methods were explored, a basic and an acidic approach (Scheme 10).  Koshikari et al. 
explored hydrolysis of esters under organic solvent-free conditions.42  From a modified procedure, 
18 was subjected to deprotection with LiOH in a methanol/water solution.  No change was 
observed when monitored by TLC, and starting material was recovered.  The reaction was 
attempted again with a 16 h reaction time, and once again no change was observed by TLC.     
It has been reported that concentrated HCl in a dioxane/water/THF solution can convert 
ethyl esters to the respective acids in moderate yields.43  When these conditions were applied to 
18,  some promising results were detected by NMR (Scheme 10).  The NMR spectrum of the crude 
sample indicated the disappearance of the ethyl group of the ester and the presence of the acid 
proton.  But after purification, no isolated compound was identified as 26.  Furthermore, without 
isolating the product, it was difficult to determine if acid 26 had formed.  The same reaction 
conditions were applied again with a longer reaction time of 16 h, but degradation was observed.  
The same conditions were applied in a microwave reactor.  The reaction was run for 30 min at the 
temperature of 100 οC, but unfortunately the solution turned black and degradation was observed.   
 




Utilizing the optimized steps from Scheme 6, initial steps to form the p-fluorophenyl aza-
carbacepham 2 were completed (Scheme 11).  With the use of 4-fluorophenylurea 27, the 
formation of the pyrimidin-2-one 28 was achieved with the same conditions as previously stated.  
A flow rate of 0.080 mL/min (120 min) was applied to the photo-flow-reactor to generate 29, 
which was subjected to ozonolysis and reductive workup to form aldehyde 30.  With the use of 
(carbethoxymethyl)triphenylphosphonium bromide under strongly basic conditions, the Wittig 
product 31 was isolated and then hydrogenated in the presence of catalytic Pd/C to make ester 32.  
Due to time restraints, the synthesis was stopped at this point.  It was observed that the fluoro 
substituent on the phenyl ring had little effect on the chemistry.  Future steps of this study will 
continue the synthesis forward with p-fluorophenyl aza-carbacepham 2 and apply the same 
conditions to synthesize p-methoxyphenyl aza-carbacepham 3 and m-fluorophenyl aza-
carbacepham 4. 
 




 Other derivatives with the aza-β-lactam ring were also attempted, such as aza-carbapenam 
33, the structure of which bears resemblance to the carbapenem class of β-lactam antibiotics 
(Figure 6).  It was hypothesized that much of the same chemistry described in Scheme 8 could be 
utilized to synthesize aza-carbapenam 33 (Scheme 12).   
 
Figure 6.  Proposed target molecule aza-carbapenam 33. 
Starting from aldehyde 8, multiple pathways were explored to homologate the alkyl chain.  
The formation of alcohol 35 was found to be very difficult.  In attempt to synthesize aza-
carbapenam 33, formation of an enol-ether followed by acidic conversion to an alcohol was 
explored using a modified procedure from Zaytsev et al.44  The reaction was performed using 
(methoxymethyl)triphenylphosphonium chloride under strongly basic conditions in a Wittig 
reaction to form 4.3:1 mixture of E- and Z-enol ethers 34a and 34b, respectively (Scheme 12).  
Unfortunately, isolated yields were low so future exploration of conditions was disregarded.  The 
acidic hydrolysis to form 35 was still attempted but was found to be inconclusive due to the small 
scale of the reaction.   




Scheme 12.  Theorized synthetic pathway to form aza-carbapenam 33. 
Hydroboration was explored as another potential method to make alcohol 35 (Scheme 15).  
Utilizing a modified procedure from Della Sala et al., methyltriphenylphosphonium bromide under 
strongly basic conditions was used in a Wittig reaction.45  The resulting alkene was then subjected 
to standard hydroboration conditions to generate the respective alcohol.45,46  The conditions were 
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applied to aza-aldehyde 8 and the isolated yield was 9%.  Because of the low yield, a sterically 
hindered aldehyde was used in a model system to optimize the conditions.   
For the model system (Scheme 13), a modified procedure was used from Bonneau et al.47 
With the use of methyl 2-phenylacetate, two consecutive methylations were completed to yield 
43.47    LiAlH4 reduction was used to produce the alcohol 44 followed by a PCC oxidation to make 
the corresponding aldehyde 45.44  With the use of 45, various bases and temperatures were 
examined to optimize the Wittig reaction for the formation of the hydroboration precursor.    
 
Scheme 13.  Synthetic pathway to make hindered aldehyde 45 for hydroboration model system. 
Model system conditions were explored to optimize the formation of 46 (Scheme 14).  The 
manner at which the ylide was generated was the first area explored.  NaH and NaHMDS were 
used as methods to generate the ylide, and it was observed that NaHMDS was more efficient 
resulting in a higher reaction yield (Table 2, entry 3).   
 
Scheme 14.  Hydroboration model system conditions optimization. 
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In attempt to further increase the reaction yield, gentle heating of the flask was explored.  
Initially the reaction was performed at 0 οC, but this was problematic due to the freezing point of 
benzene (~5.5 οC).  The reaction temperature was warmed to rt, and a small increase of product 
formation was observed.  Finally, the reaction temperature was increased slowly to 60 οC which 
resulted in a 42% yield of product 46 (Table 2, entry 5). 






1 NaH rt 21 
2 NaH 50 4 
3 NaHMDS 0 → rt 35 
4 NaHMDS rt 37 
5 NaHMDS 60 42 
 
The optimized conditions from the model system were applied to aldehyde 8.  A large 
increase in isolated yield was observed of 9% to 39%.  With the formation of 47, initial attempts 
to form 35 were explored.  With a modified procedure from Morrill et al., the hydroboration was 
attempted (Scheme 15).46  BH3·THF solution was added to 47 followed by NaOH/H2O2 and the 
isolated spot was examined by NMR analysis.  It was observed that the alkene was converted to 




Scheme 15.  Attempted hydroboration to form aza-alcohol 35. 
 In conclusion, a synthetic pathway utilizing an N-alkylated aldol ring closure was explored 
in pursuit to produce aza-carbacepham 1.  The 4π electrocyclization was optimized with the use 
of flow chemistry to form 7.  Deprotection of TBDMS ether 22 with Bu4NF to form alcohol 23 
was found to be low yielding.  An additional method was explored with the use of NIS, but no 
reaction was observed.  The small amount of 23 was continued on to make aza-carbacephen 25.  
With the general pathway determined, initial steps to form p-fluorophenyl aza-carbacepham 2 were 
completed.  The synthetic pathway can then be applied to make the respective p-methoxyphenyl 
aza-carbapenam 3 and m-fluorophenyl aza-carbapenam 4.  Synthesis of aza-carbapenem 33 was 
explored by enol-ether followed by acidic conversion to alcohol 35, which was found to be 
unsuccessful.  A different pathway utilized hydroboration of 47 to form the unexpected product 
48.  Once a large library of aza-β-lactam derivatives have been synthesized, the inhibition ability 
against β-lactamase will be tested.  Positive results could influence the redesign of second 






-Chapter 2-  
-Introduction-  
Methicillin was introduced to the market in 1959 as a new method for treatment of bacterial 
infections caused by penicillin-resistant Staphylococcus aureus.18  Unfortunately, isolates were 
identified in the United Kingdom that had acquired resistance to methicillin in 1961.18  MRSA 
isolates were later observed in European countries, Japan, Australia, and the United States.18  
MRSA has become a growing problem in hospitals due to the pathogen’s ability to protect itself 
against many members of the β-lactam antibiotic family.48  The resistance was brought on by the 
development of the methicillin resistance gene (mecA), which encodes the methicillin-resistant 
PBP2a to have a low binding affinity for the antibiotic.18  Glycopeptide antibiotics, such as 
vancomycin, have been successfully used to treat various MRSA strains.  Unfortunately, 
Staphylococcus aureus strains have begun to build resistance to vancomycin. Isolation of 
vancomycin-intermediate, and most recently vancomycin-resistant Staphylococcus aureus 
(VRSA) carrying the vanA gene have brought on the need for new treatment options.  A new class 
of antibiotics, oxazolidinones, are synthetic drugs that are active against a large spectrum of Gram-
positive bacteria, including methicillin and vancomycin-resistant staphylococci, vancomycin-
resistant enterococci, penicillin-resistant pneumococci and anaerobes.49  In 2000 the FDA 
approved an oxazolidinone, linezolid (figure 7), for treatment of complicated skin infections 
caused by MRSA.49  During the subsequent years of clinical use, emergence of resistance to 




Figure 7.  Linezolid, a clinically used oxazolidinone. 
The Boudreau research group at University of New Hampshire discovered that rapamycin 
potentiates the activity of oxacillin against various strains of MRSA (Table 3).  In the presence of 
rapamycin, the minimum inhibitory concentration (MIC) of oxacillin was substantially decreased, 
but how rapamycin potentiates the activity of oxacillin is unknown.   




 - Rapamycin + Rapamycin 
MRSA252 265 256 
NRS123 16 1 
NRS70 32 8 
 
Rapamycin was discovered in soil samples on Easter island in 1969 and it was originally 
studied for its antifungal ability, until it was also found to prevent cell multiplication.50   In 1987, 
rapamycin was found to also have immunosuppressant abilities, and in 1999, the FDA approved 
rapamycin as an antirejection drug prescribed to kidney transplant patients.50  Further studies of 
rapamycin has discovered the molecule’s good permeability across the blood-brain barrier.51  
Rapamycin has been found to have a wide variety of research applications, where it has been 
engineered to control gene function through rapamycin-induced transcription as well as protein 
localization, protein degradation, and DNA recombination.52,53  
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From extensive analysis, four chemically accessible locations have been identified for 
modification of rapamycin (Figure 8).  The methoxy group, denoted at position A, was found to 
undergo nucleophilic substitution and β-elimination under acidic conditions.54  The hydroxyl 
group at position B has been utilized due to the easy protection with silyl groups.55,56  The lactone 
at position C, can be hydrolyzed and eliminated.57  The hydroxyl group at position D has been 
found to be easily converted to a carbonate group and esterified.57  With the various areas for 
chemical accessibility, methods such as photoaffinity labeling can be utilized to study the 
interaction of rapamycin with large biomolecules.   
 
Figure 8.  The structure of rapamycin with four chemically accessible locations, denoted A-D. 
Analyzing the molecular interaction between bioactive ligands and their protein targets is 
an important step in drug design.  Understanding how these interactions take place allows for the 
discovery of new and potentially more efficient drugs.58  With the use of a photoaffinity group, a 
highly reactive species is generated to induce a covalent bond between the ligand and the protein 
in a nonselective manner.58  The photophore is affixed to the ligand of interest, and with the use 
of select wavelengths of light, a reactive species will form a nonselective bond to the nearby 
biomolecule (Scheme 16).  Successful applications of photoaffinity labeling can result in the 
identification of target biomolecules in crude extracts with the aid of a radioisotope-labeled probe, 
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which are highly sensitive detection tags.58  An additional advantage of photoaffinity labeling is 
the ability to identify the ligand binding site and labeled amino acid.  Unfortunately, identification 
of photolabeled compounds can be difficult due to low photoincorporation yields.59  Multiple 
options are available to combat the low photoincorporation yields such as: choice and synthesis of 
the photophore, irradiation conditions, and choice of tag for the identification of the biomolecule.58 
 
Scheme 16.  Schematic representation of the process of photoaffinity labeling. 
Specific groups such as aryl azides, benzophenones, or aryldiazirines (Scheme 17) have 
been found to be very useful due to the highly reactive species they generate.58  The aryl azides 
are photoactivated to generate a nitrene at wavelengths below 300 nm, but low wavelengths of 
light have been observed to cause damage to biomolecules, while benzophenones are radiated at 
350 nm to generate a reactive triplet carbonyl state.60  The ground state carbonyl compound can 
be regenerated so the photoreactive group is reusable, but long photoirradiation times are required 
for this labeling process.58  Aryldiazirines generate a carbene when radiated with light at 360 nm, 
which rapidly forms a covalent bond to biomolecules and does not require long photoirradiation 




Scheme 17.  Photochemical groups with generated reactive species that are commonly used in 
photoaffinity labeling. 
It is crucial to limit interference when the photoaffinity probe is attached to the target 
molecule.  The target molecule must act as normal in order to properly study the molecular 
interactions.  Size is a large factor in this consideration, and the aliphatic diazirine linkers have 
been found to minimize the issue of interference.  The benefit of the aliphatic diazirine linker is 
the overall small size, which will minimize interference with protein binding, and still maintain 
the short irradiation time.62  Coupling the small size of the probe with a terminal alkyne as the 
reporter, the cross-linked protein probe complex can be used for various biochemical analysis, 
such as pull-down assays and LC-MS/MS, for the identification of the protein target.62  Since the 
manner that rapamycin potentiates the activity of oxacillin to inhibit various strains of MRSA is 
not understood, the molecular interactions can be studied by attaching an aliphatic diazirine linker 






-Results and discussion- 
 The mechanism of interaction will be studied by attaching an aliphatic diazirine linker to 
rapamycin.  Li et al. explored multiple small aliphatic diazirine linkers that could be used as 
photoaffinity linkers.62  With the use of the diazirine linker 49, the mechanism of interaction with 
oxacillin and MRSA can be studied.  The hydroxyl group on the cyclohexane ring, Figure 8 
position D, is the location the linker is predicted to be installed to form rapa-linker 50.63 
 
Figure 9.  Aliphatic diazirine linker 49 and respective rapa-linker 50. 
 Diazirine linker 49 was prepared following the synthetic pathway from Li et al. (Scheme 
18).62  The synthesis started with the alkylation of ethyl acetoacetate to form 52, which was 
followed by the protection of the ketone with ethylene glycol to form 53.62,64  The ester was 
reduced with LiAlH4 to give the respective alcohol 54, which was deprotected with p-
toluenesulfonic acid to give ketone 55.62  The formation of the diazirine ring was a multiple step 
process that began with heating to reflux the ketone in anhydrous ammonia followed by the 
addition of hydroxylamine-O-sulfonic acid to form the intermediate diaziridine. With the use of 
an iodine solution, the diaziridine ring was oxidized to form corresponding diazirine 56, which 




Scheme 18.  Synthesis of linker 49 that will be used to alkylate rapamycin. 
With the synthesis of linker 49 complete, alkylation attempts of rapamycin were examined.  
Rodrik-Outmezguine et al. studied the functionalization of rapamycin, and modifying the research 
with linker 49, initial attempts to alkylate rapamycin were performed (Scheme 19).63 
 
Scheme 19.  Alkylation of rapamycin to form respective rapa-linker 50. 
The alkylation reaction of rapamycin was monitored by TLC over time, and a new spot 
formation was observed.  The new spot was isolated, then examined by NMR.  Unfortunately, the 
data from the resulting spectra was unclear and difficult to determine if the rapa-linker 50 was 
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truly formed.  Calculations performed with NMR prediction software showed similarities when 
compared to the 13C NMR of the isolated product, but the data was inconclusive due to the small 
amount of the sample isolated.  In order to fully characterize the product, more would need to be 
synthesized. 
 The synthesis of diazirine linker 49 was successfully completed.  Initial alkylation attempts 
of rapamycin have yielded inconclusive results.  Future direction of the project would explore 
other alkylation techniques to attach the linker to rapamycin.  With the formation of rapa-linker 
50, the interaction with oxacillin and MRSA can be examined.  The rapamycin-protein complex 
can be isolated from the solution using a pull-down assay, followed by MS/MS analysis to 















I. Reagents and Solutions 
 All reagents and solvents employed were purchased from Acros Organics Ltd. (Hampton, 
NH), Alfa-Aesar Chemicals. (Haverhill, MA), MilliporeSigma Chemical Company (St. Louis, 
MO), Oakwood Products, Inc. (Estill, SC), or TCI American Chemicals. (Portland, OR) unless 
specifically stated. 
 All reagents and solvents were of American Chemical Society (ACS) grade and were used 
without further purification unless otherwise stated. All reactions were performed under a positive 
pressure of nitrogen using oven or flame-dried glassware. All organic solvents when stated dry 
were prepared by addition of dried over molecular sieves prior to use. For the removal of solvent, 
in vacuo refers to evaporation under reduced pressure below 40 οC using a rotary evaporator 
followed by evacuation (< 0.1 mm Hg) to a constant sample mass.  Saturated solutions of NH4Cl, 
NaHCO3, HCl, and NaOH refer to aqueous solutions. Brine refers to a saturated solution of NaCl. 
 
II. Purification Techniques  
 All reactions and fractions obtained from column chromatography were monitored by thin-
layer chromatography (TLC) using glass-backed plates (1.5 x 5 cm) pre-coated with silica gel 






III. Instrumentation of Compound Characterization  
 Nuclear magnetic resonance (NMR, 500 MHz) spectra were obtained on a Varian Mercury 
400, 500 MHz spectrometers.  1H NMR chemical shifts are reported in parts per million (PPM) 
relative to tetramethylsilane as the internal standard relative to the solvent of CDCl3 (δ 7.26) and 
coupling constant values are given in [Hz]. The following abbreviations are given for spin 
multiplicity: s = singlet, d = doublet, t = triplet, m = multiplet, dt = doublet of triplets, ddd = 
doublets of doublets of doublets, td = triplet of doublets, qd = quartet of doublets. Additional 
assignments were made using homonuclear correlation spectroscopy (g-COSY), heteronuclear 
single quantum coherence spectroscopy (gHSQC) and heteronuclear multiple bond correlation 
spectroscopy (gHMBC).  All literature compounds had 1H NMR spectrum consistent with the 
assigned structures. 
 
IV. Experimental procedures and Data 
1,2-Dihydro-N-phenyl-4,6-dimethylpyrimidin-2-one (6)  
This known compound was prepared according to the procedure from 
Muthuraman et al.30  Phenyl urea (5.45 g, 40.00 mmol) was dissolved in 95% 
EtOH (50 mL) with conc. hydrochloric acid (10 mL) and stirred at room temperature for 5 min.  
Acetyl acetone (4.81 g, 48.00 mmol) was added to the solution and stirred at reflux for 3 h.  The 
reaction mixture was cooled in an ice/water bath and the resulting solid was isolated by vacuum 
filtration and washed with cold EtOH (3 x 30 mL).  The white solid was dissolved in water (40 
mL) and then brought to a pH of 8-10 with a sodium hydroxide solution (3.5 M, 5 mL).  The 
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solution was extracted with CHCl3 (3 x 50 mL), and the combined organic layers were dried with 
MgSO4 then concentrated in vacuo to yield a white solid (3.6423 g, 46%): 
1H NMR (CDCl3, 500 
MHz) δ 7.55 – 7.21 (m, 5H, ArH), 6.20 (d, J = 0.8 Hz, 1H, C=CH), 2.42 (s, 3H, CH3), 1.99 (d, J 
= 0.8 Hz, 3H, CH3). 
3-Phenyl-4,6-dimethyl-2-oxo-1,3-diazabicyclo(2.2.0)hex-5-ene (7) 
This known compound was prepared according to the procedure of Chandrakala 
et al.26  Pyrimidinone 6 (1.20 g, 6.00 mmol) was suspended in benzene (350 mL) 
and stirred at room temperature for 16 h.  The solution was partitioned into 5 equal 
portions and placed into quartz test tubes then irradiated with light (300 nm) for 3 h.  The test tubes 
were combined, and the solution concentrated in vacuo.  The sample was purified by column 
chromatography (SiO2, 20 % EtOAc/hexanes) to yield a yellow solid (0.3227 g, 27%): 
1H NMR 
(CDCl3, 500 MHz) δ 7.43 – 7.09 (m, 5H, ArH), 6.15 (q, J = 1.7 Hz, 1H, vinyl CH), 2.13 (d, J = 
1.7 Hz, 3H, CH3), 1.88 (s, 3H, CH3). 
 
3-Phenyl-4,6-dimethyl-2-oxo-1,3-diazabicyclo(2.2.0)hex-5-ene (7) 
This known compound was prepared according to a modified procedure from 
Chandrakala et al.26  Pyrimidinone 6 (1.00 g, 4.90 mmol) was suspended in 
benzene (300 mL) and stirred for 16 h.  The solution was passed through photo-
flow-reactor (50 mL BD glass syringe, 0.080 mL/min, 300 nm) and the solution exited into a 
collection flask with benzene (~50 mL).  The combined solution was concentrated in vacuo, and 
purified by column chromatography (SiO2, 20 % EtOAc/hexanes) to yield a yellow solid (0.6224 
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g, 62%): 1H NMR (CDCl3, 500 MHz) δ 7.43 – 7.09 (m, 5H, ArH), 6.15 (q, J = 1.7 Hz, 1H, vinyl 
CH), 2.13 (d, J = 1.7 Hz, 3H, CH3), 1.88 (s, 3H, CH3). 
 
1-Phenyl-3-acetyl-4-formyl-4-methyl-1,3-diazetidin-2-one (8) 
This known compound was prepared according to the procedure from Chandrakala 
et al.26  Alkene 7 (0.55 g, 2.70 mmol) was dissolved in CH2Cl2 (120 mL) and 
cooled to -78 οC.  A steady stream of ozone was bubbled through the solution at   
-78 οC until blue color persisted.  O2 was bubbled through the solution until the solution became 
colorless then was slowly warmed to rt.  The mixture was cooled to 0 οC, then dimethyl sulfide 
(1.00 mL, 0.85 g, 13.60 mmol) was added dropwise and the reaction mixture was warmed to rt 
then stirred for 2 h.  The reaction mixture was concentrated in vacuo, then purified by column 
chromatography (SiO2, 20 % EtOAc/hexanes) to yield faint yellow solid (0.3785 g, 60%): 
1H NMR 
(CDCl3, 500 MHz) δ 9.45 (d, J = 0.5 Hz, 1H, CHO), 7.38– 7.12 (m, 5H, ArH), 2.48 (s, 3H, 
COCH3), 1.95 (d, J = 0.5 Hz, 3H, CH3). 
 
(4-Ethoxy-4-oxobutyl)triphenylphosphonium bromide (9) 
This known compound was prepared according to the procedure from Luo et 
al.35  Triphenylphosphine (3.76 g, 14.34 mmol) was dissolved in dry toluene 
(20 mL) and stirred at rt for 5 min.  Ethyl-4-bromobutyrate (1.47 mL, 2.00 g, 10.25 mmol) was 
added dropwise to reaction flask and heated to 125 οC for 16 h.  The reaction flask was cooled to 
rt then Ch2Cl2 (10 mL) was added, followed by Et2O (~80 mL) until white precipitate formation 
stopped.  The solid was isolated by vacuum filtration and washed with Et2O (~100 mL) and dried 
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to yield pure white solid (3.1498 g, 81%): 1H NMR (CDCl3, 400 MHz) δ 7.94 – 7.68 (m, 15H, 
ArH), 4.15 – 4.08 (m, 4H, OCH2 and PCH2), 2.92 (td, J = 6.5, 1.4 Hz, 2H), 1.98 – 1.89 (m, 2H, 
CH2), 1.25 (t, J = 7.1 Hz, 3H, CH2CH3). 
 
(Z)-Ethyl 5-(1-acetyl-2-methyl-4-oxo-3-phenyl-1,3-diazetidin-2-yl)pent-4-enoate (10) 
This compound was prepared according to a modified procedure from Luo 
et al.35  Phosphonium Bromide salt 9 (0.82 g, 1.80 mmol) was suspended in 
dry THF (10 mL) and cooled to -78 οC.  NaHMDS solution (1 M in THF, 
2.25 mL, 2.25 mmol) was added to reaction flask and stirred for 5 min at -78 οC.  Aldehyde 8 (0.35 
g, 1.50 mmol) in THF (5 mL) was added dropwise to the reaction flask, then allowed to warm up 
to rt and stir for 16 h.  The reaction mixture was diluted with EtOAc (10 mL) followed by water 
(15 mL).  The resulting layers were separated, and the aqueous layer was extracted with EtOAc (3 
x 15 mL).  The combined organic layers were dried with MgSO4 and then concentrated in vacuo.  
The sample was purified by column chromatography (SiO2, 10 % EtOAc/hexanes) to yield yellow 
oil (0.0770 g, 16%): 1H NMR (CDCl3, 500 MHz,) δ 7.39  – 7.07 (m, 5H, ArH), 5.78 (dt, J = 11.9, 
7.2 Hz, 1H, vinyl CH), 5.67 (dt, J = 11.9, 1.9 Hz, 1H, vinyl CH), 4.09 (qd, J = 7.1, 2.1 Hz, 2H, 
OCH2), 2.58 – 2.50 (m, 1H), 2.44 – 2.40 (m, 4H, 2 x CH2), 2.32 – 2.25 (m, 2H, CH2), 2.03 (s, 3H, 
CH3), 1.23 (t, J = 7.1 Hz, 3H, CH2CH3); 
13C NMR (CDCl3, 126 MHz) δ 172.31, 165.31, 154.12, 
146.20, 137.82, 129.42, 124.96, 123.71, 115.93, 80.86, 60.51, 33.47, 24.16, 23.06, 22.89, 14.17; 







Ethyl 5-(1-acetyl-2-methyl-4-oxo-3-phenyl-1,3-diazetidin-2-yl)pentanone (11) 
This compound was prepared according to a modified procedure from 
Chandrakala et al.26  Ester 10 (0.08 g, 0.23 mmol) was dissolved in EtOAc 
(10 mL) and flushed with N2 for 5 min.  10 % Pd/C (0.03 g) was added to 
reaction flask and flushed with N2 for additional 5 min.  H2 was bubbled through the solution for 
10 min, then the mixture was stirred under H2 environment for 4 h.  The reaction mixture was 
filtered through a celite pad, then washed with EtOAc (25 mL).  The filtrate was concentrated in 
vacuo which afforded a colorless oil (0.0809 g, 99%) with no further purification: 1H NMR 
(CDCl3, 500 MHz) δ 7.38 – 7.09 (m, 5H, ArH), 4.08 (q, J = 7.1 Hz, 2H, OCH2), 2.51 – 2.43 (m, 
1H), 2.41 (s, 3H, COCH3), 2.27 – 2.20 (m, 2H, CH2), 1.91 (s, 3H, CH3), 1.66 – 1.58 (m, 2H, CH2), 
1.21 (t, J = 7.1 Hz, 3H, CH2CH3); 
13C NMR (CDCl3, 126 MHz) δ 173.17, 166.23, 153.95, 146.10, 
129.59, 123.75, 116.04, 82.57, 60.29, 34.23, 33.97, 24.30, 22.95, 22.17, 18.62, 14.17; HRMS 




This known compound was prepared according to a procedure from Chandrakala 
et al.26  LiAlH4 (0.02 g, 0.50 mmol) was suspended in Et2O (8 mL) and cooled 
to 0 οC.  Aldehyde 8 (0.03 g, 0.12 mmol) in Et2O (3 mL) was added dropwise to 
reaction flask and stirred for 1 h at 0 οC.  The reaction mixture was quenched with NaOH (1 M, 1 
mL) followed by water (2 mL) and the resulting solution was filtered through a celite pad. The 
filtrate was extracted with Et2O (3 x 10 mL), and the combined organic layers were dried with 
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MgSO4 then concentrated in vacuo.  The sample was purified by column chromatography (SiO2, 
50 % EtOAc/hexanes) to yield faint yellow oil (0.0184 g, 80%): 1H NMR (CDCl3, 500 MHz,) δ 
7.35 – 7.07 (m, 5H, ArH), 5.02 (s, 1H, NH), 4.03 – 3.87 (m, 2H, OCH2), 1.75 (s, 3H, CH3). 
 
(E)-Ethyl 3-(1-acetyl-2-methyl-4-oxo-3-phenyl-1,3-diazetidin-2-yl)acrylate (18) 
This known compound was prepared according to the procedure from 
Chandrakala et al.26  (Carbethoxymethyl)triphenylphosphonium bromide 
salt (0.85 g, 1.98 mmol) was suspended in dry benzene (9 mL) and stirred 
at rt for 5 min. NaH (60% in mineral oil, 0.8 g, 2.1 mmol) was added to the suspension and stirred 
for 5 min.  Aldehyde 8 (0.23 g, 0.99 mmol) in dry benzene (6 mL) was added dropwise to reaction 
flask and stirred for 16 h at rt.  The reaction mixture was diluted with water (12 mL) and the 
resulting solution was separated, and the aqueous layer was extracted with Et2O (3 x 10 mL).  The 
combined organic layers were dried with MgSO4 and concentrated in vacuo.  The sample was 
purified by column chromatography (SiO2, 20 % EtOAc/hexanes) to yield faint yellow oil (0.2375 
g, 79%): 1H NMR (CDCl3, 500 MHz,) δ 7.35-7.12 (m, 5H, ArH), 7.07 (d, J = 15.9 Hz, 1H, vinyl 
CH), 6.33 (d, J = 15.9 Hz, 1H, vinyl CH), 5.31 (s, 1H, NH), 4.23 (qd, J = 7.2, 0.8 Hz, 2H, OCH2), 
2.41 (s, 2H, COCH3), 2.07 (s, 3H, CH3), 1.29 (dt, J = 20.6, 7.2 Hz, 3H, CH2CH3). 
 
Ethyl 3-(1-acetyl-2-methyl-4-oxo-3-phenyl-1,3-diazetidin-2-yl)propanate (19) 
This known compound was prepared according to the procedure from 
Chandrakala et al.26  Trans ester 18 (0.24 g, 0.79 mmol) was dissolved in 
EtOAc (30 mL) and flushed with N2 for 5 min.  10 % Pd/C (0.06 g) was 
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added to the reaction flask and then flushed with N2 for additional 5 min.  H2 was bubbled through 
solution for 10 min, then the mixture was stirred under H2 environment for 4 h.  The reaction 
mixture was filtered through a celite pad and washed with EtOAc (25 mL).  The solution was 
concentrated in vacuo to yield colorless oil (0.2745 g, 99%) with no further purification: 1H NMR 
(CDCl3, 500 MHz) δ 7.37 –7.08 (m, 5H, ArH), 4.01 (q, J = 7.2 Hz, 2H, OCH2), 2.77 (ddd, J = 
15.4, 9.0, 6.5 Hz, 1H, CH2), 2.48 (ddd, J = 15.4, 8.4, 7.0 Hz, 1H, CH2), 2.40 (s, 3H, COCH3), 2.34 
(ddd, J = 8.8, 6.6, 3.0 Hz, 2H, CH2), 1.92 (s, 3H, CH3), 1.18 (t, J = 7.2 Hz, 3H, CH2CH3). 
 
4-(3-Hydroxypropyl)-4-methyl-1-phenyl-1,3-diazetidin-2-one (20) 
This known compound was prepared according to the procedure from 
Chandrakala et al.26  LiAlH4 (0.02 g, 0.45 mmol) was suspended in Et2O (20 
mL) and cooled to 0 οC.  Ester 19 (0.14 g, 0.45 mmol) in Et2O (2 mL) was 
added dropwise to the reaction flask and stirred for 1 h at -10 οC.  The reaction mixture was 
quenched with NaOH solution (1 M, 1 mL) followed by water (5 mL), and the resulting mixture 
was filtered through a celite pad.  The aqueous layer was extracted with Et2O (3 x 10 mL) and the 
combined organic layers were dried with MgSO4 then concentrated in vacuo.  The sample was 
purified by column chromatography (SiO2, 80 % EtOAc/hexanes) to yield colorless oil (0.0458 g, 
49%): 1H NMR (CDCl3, 500 MHz) δ 7.35 –7.04 (m, 5H, ArH), 5.13 (s, 1H, NH), 3.69 (dt, J = 
10.7, 6.5 Hz, 2H, OCH2), 2.14 (ddd, J = 8.3, 6.5, 1.3 Hz, 2H, CH2), 1.80 (dt, J = 7.2, 1.6 Hz, 1H, 






This known compound was prepared from a modified procedure from 
Chandrakala et al.26  Alcohol 20 (0.06 g, 0.26 mmol) was dissolved in 
CH2Cl2 (3 mL) and cooled to 0 
οC.  Imidazole (0.18 g, 2.60 mmol) was 
added to the reaction flask, followed by DMAP (0.002 g, 0.02 mmol) and the resulting solution 
was stirred at 0 οC for 5 min.  To the reaction flask, tert-butyldimethylsilyl chloride (0.20 g, 1.30 
mmol) was added and the mixture was stirred for 1 h at 0 οC.  The reaction was diluted with water 
(3 mL), and the resulting layers were separated.  The aqueous layer was extracted with CH2Cl2 (3 
x 5 mL).  The combined organic layers were dried with MgSO4 and concentrated in vacuo.  The 
sample was purified by column chromatography (SiO2, 40 % EtOAc/hexanes) to yield colorless 
oil (0.0985 g, 99%): 1H NMR (CDCl3, 500 MHz) δ 7.34 – 7.03 (m, 5H, ArH), 5.14 – 5.13 (s, 1H, 
NH), 3.66 – 3.61 (m, 2H, SiOCH2), 2.10 (dd, J = 8.2, 7.2 Hz, 2H, CH2), 1.86 – 1.77 (m, 1H, CH2), 
1.75 (s, 3H, CH3), 1.59 – 1.55 (m, 1H, CH2), 0.91 (d, J = 17.3 Hz, 9H, SiC(CH3)), 0.12 (s, 3H, 
SiCH3), 0.05 (s, 3H, SiCH3). 
 
Ethyl 2-(2-(3-((tert-butyldimethylsilyl)oxy)propyl)-2-methyl-4-oxo-3-phenyl-1,3-diazetidin-
1-yl) acetate (22) 
This known compound was prepared according to the procedure from 
Chandrakala et al.26  NaH (60% in mineral oil, 0.06 g, 1.56 mmol) was 
suspended in dry THF (5 mL) and cooled to 0 οC.  TBDMS ether 21 
(0.13 g, 0.39 mmol) in THF (6 mL) was added dropwise to reaction flask and stirred at 0 οC for 10 
min.  Ethyl bromoacetate (0.22 mL, 0.33 g, 1.95 mmol) added dropwise, then the reaction flask 
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was warm to rt and stirred for 2 h.  The reaction mixture was diluted with water (6 mL) and the 
resulting layers separated.  The aqueous layer was extracted with EtOAc (3 x 5 mL), and the 
combined organic layers were dried with MgSO4 then concentrated in vacuo.  The sample was 
purified by column chromatography (SiO2, 20 % EtOAc/hexanes) to yield colorless oil (0.2077 g, 
99%): 1H NMR (CDCl3, 500 MHz) δ 7.32 –7.00 (m, 5H, ArH), 4.22 (q, J = 7.2 Hz, 2H, OCH2), 
4.01 (d, J = 5.8 Hz, 2H, NCH2), 3.58 (t, J = 6.0 Hz, 2H, SiOCH2), 2.15 – 2.02 (m, 2H, CH2), 1.72 
(s, 3H, CH3), 1.70 – 1.60 (m, 2H, CH2), 1.31 (t, J = 7.1 Hz, 3H, OCH2CH3), 0.87 (s, 9H, SiC(CH3)), 
0.01 (s, 3H, SiCH3), -0.01 (s, 3H, SiCH3). 
 
Ethyl 2-(2-(3-hydroxypropyl)-2-methyl-4-oxo-3-phenyl-1,3-diazetidin-1-yl) acetate (23)          
This known compound was prepared according to the procedure from 
Chandrakala et al.26  N-alkylated TBDMS ether 22 (0.02 g, 0.04 mmol) was 
dissolved in dry THF (1 mL) and cooled to 0 οC.  Tetrabutylammonium 
fluoride (1 M in THF, 0.09 mL, 0.09 mmol) was added dropwise to reaction flask and stirred for 
1 h at 0 οC.  The reaction mixture was diluted with brine (3 mL) and the resulting layers separated.  
The aqueous layer was extracted with EtOAc (3 x 5 mL), and the combined organic layers were 
dried with MgSO4 then concentrated in vacuo.  The sample was purified by column 
chromatography (SiO2, 80 % EtOAc/hexanes) to yield colorless oil (0.0082 g, 62%): 
1H NMR 
(CDCl3, 500 MHz) δ 7.33 – 7.01 (m, 5H, ArH), 4.23 (qd, J = 7.1, 2.3 Hz, 2H, OCH2), 4.14 (d, J = 
18.3 Hz, 1H, NCH2), 3.90 (d, J = 18.3 Hz, 1H, NCH2), 3.71 – 3.55 (m, 2H, OCH2), 2.16 (ddd, J = 
9.8, 7.3, 5.3 Hz, 2H, CH2), 1.87 – 1.77 (m, 1H, CH2), 1.72 (s, 3H, CH3), 1.52 – 1.42 (m, 1H, CH2), 
1.31 (t, J = 7.1 Hz, 3H, OCH2CH3). 
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Ethyl 2-(2-methyl-4-oxo-2-(3-oxopropyl)-3-phenyl-1,3-diazetidin-1-yl) acetate (24) 
This known compound was prepared according to the procedure from 
Chandrakala et al.26  Alcohol 23 (0.008 g, 0.03 mmol) was dissolved in CH2Cl2 
(1 ml) and then the mixture was cooled to 0 οC.  Pyridinium chlorochromate 
(0.01 g, 0.06 mmol) was added, then the reaction flask was warmed to rt and stirred for 2 h.  The 
reaction mixture was diluted with Et2O (2 mL) then filtered through a celite pad and washed with 
Et2O (3 x 2 mL).  The filtrate was concentrated in vacuo to yield a colorless oil (0.0055 g, 60%) 
with no further purification: 1H NMR (CDCl3, 500 MHz) δ 9.75 (s, 1H, CHO), 7.31 – 6.99 (m, 
5H, ArH), 4.22 (qd, J = 7.1, 3.1 Hz, 2H, OCH2), 4.13 (d, J = 18.4 Hz, 1H, NCH2), 3.82 (d, J = 18.3 
Hz, 1H, NCH2), 2.92 – 2.82 (m, 1H, CH2), 2.45 – 2.32 (m, 3H, 2 x CH2), 1.74 (s, 3H, CH3), 1.30 
(t, J = 7.1 Hz, 3, OCH2CH3). 
 
Ethyl 6-methyl-8-oxo-7-phenyl-1,7-diazabicyclo[4.2.0]oct-2-ene-2-carboxylate (25) 
This known compound was prepared according to the procedure from 
Chandrakala et al.26  NaH (60% in mineral oil, 0.005 g, 0.12 mmol) was 
suspended in dry THF (0.5 mL) and the reaction flask was cooled to 0 οC.  
Aldehyde 24 (0.006 g, 0.02 mmol) in THF (1 mL) was added dropwise to the reaction flask and 
stirred for 1 h at 0 οC.  The reaction mixture was diluted with Et2O (3 mL), then filtered through a 
celite pad and washed with Et2O (3 x 2 mL).  The collected filtrate was concentrated in vacuo, and 
purified by preparative thin-layer chromatography (40 % EtOAc/hexanes) to yield aza-
carbacephem (0.0019 g, 39%): 1H NMR (CDCl3, 500 mHz) δ 7.34 – 7.04 (m, 5H, ArH), 6.37 – 
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6.33 (m, 1H, vinyl CH), 4.45 – 4.30 (m, J = 7.1 Hz, 2H, OCH2), 2.56 – 2.49 (m, 2H, CH2), 1.79 
(td, J = 12.6, 5.1 Hz, 2H, CH2), 1.67 (d, J = 0.8 Hz, 3H, CH3), 1.39 (t, J = 7.1 Hz, 3H, OCH2CH3). 
 
(E/Z)-1-Acetyl-4-(2-methoxyvinyl)-4-methyl-3-phenyl-1-3-diazetidin-2-one (34a, 34b) 
These compounds were prepared according to a modified 
procedure from Della et al.45   
(Methoxymethyl)triphenylphosphonium chloride (0.86 g, 2.51 
mmol) was suspended in dry THF (8 mL) and the reaction flask was cooled to -78 οC.  NaHMDS 
(1 M in THF, 2.40 mL, 2.40 mmol) was added dropwise to the reaction flask and stirred for 5 min 
at -78 οC.  Aldehyde 8 (0.29 g, 1.25 mmol) in THF (4 mL) was added dropwise, then the reaction 
flask allowed to warm to rt and stir for 16 h.  The mixture was diluted with water (8 mL) followed 
by Et2O (8 mL).  The resulting layers were separated, and the aqueous layer was extracted with 
Et2O (3 x 10 mL).  The combined organic layers were dried with MgSO4 and concentrated in 
vacuo.  The sample was purified by column chromatography (SiO2, 20 % EtOAc/hexanes) to yield 
solid in a 4.3:1 mixture of E/Z isomers (0.0303 g, 9%): 1H NMR (CDCl3, 500 MHz) δ 7.37 – 7.09 
(m, 5H, ArH), 6.90 (d, J = 12.9 Hz, 1H, vinyl CH), 5.03 (d, J = 12.9 Hz, 1H, vinyl CH), 3.61 (s, 
3H, OCH3), 2.39 (s, 3H, COCH3), 2.02 (s, 3H, CH3); 
13C NMR (CDCl3, 126 MHz) δ 165.55, 
153.53, 146.35, 135.82, 129.35, 123.49, 116.06, 110.00, 100.33, 56.52, 23.20, 21.28; HRMS 








This known compound was prepared according to the procedure from Bonneau et 
al.47  N-Diisopropylamine (16.91 mL, 12.14 g, 120.00 mmol) and bipyridyl (0.003 
g, 0.02 mmol) were dissolved in dry THF (120 mL) and the reaction flask was cooled to -78 οC.  
n-BuLi (1.6 M in THF, 75 mL, 120.00 mmol) was added dropwise to reaction flask and stirred at 
-78 οC for 5 min.  Methyl phenylacetate (4.22 mL, 4.50 g, 30 mmol) in THF (50 mL) was added 
to the reaction flask and stirred for 15 min at -78 οC.  Iodomethane (9.34 mL, 21.29 g, 150.00 
mmol) was added dropwise and the reaction mixture was allowed to slowly warm to rt and stir for 
3 h.  The mixture was diluted with water (100 mL) followed by CH2Cl2 (100 mL) and the resulting 
layers were separated.  The aqueous layer was extracted with CH2Cl2 (3 x 80 mL), and the 
combined organic layers were dried with MgSO4 and concentrated in vacuo.   
In a new dry flask, additional portion of N-diisopropylamine (16.91 mL, 12.14 g, 120.00 mmol) 
and bipyridyl (0.003 g, 0.02 mmol) were dissolved in dry THF (120 mL) and cooled to -78 οC.     
n-BuLi (1.6 M in THF, 75 mL, 120.00 mmol) was added dropwise to reaction flask and stirred at 
-78 οC for 5 min.  The crude sample from before in THF (50 mL) was added dropwise to reaction 
flask and stirred for 15 min at -78 οC.  Iodomethane (9.34 mL, 21.29 g, 150.00 mmol) was added 
dropwise and then the reaction flask was warmed to rt and stirred for 3 h.  The mixture was diluted 
with water (100 mL) followed by CH2Cl2 (100 mL) and resulting layers were separated.  The 
aqueous layer was extracted with CH2Cl2 (3 x 80 mL) and the combined organic layers were dried 
with MgSO4 then concentrated in vacuo.  The sample was purified by column chromatography 
(SiO2, 5 % EtOAc/hexanes) to yield colorless oil (3.6706 g, 69%): 
1H NMR (CDCl3, 500 MHz) δ 





This known compound was prepared according to a modified procedure from 
Zaysev et al.44  LiAlH4 (0.85 g, 22.40 mmol) was suspended in dry Et2O (100 mL) 
and the reaction flask was cooled to 0 οC.  43 (1.00 g, 5.60 mmol) in Et2O (20 mL) was added 
dropwise and the reaction flask and was stirred for 1 h at 0 οC.  The reaction mixture was diluted 
with water (40 mL) and filtered through a celite pad.  The filtrate was extracted with Et2O (3 x 30 
mL), and the combined organic layers were dried with MgSO4 then concentrated in vacuo.  The 
sample was purified by column chromatography (SiO2, 20 % EtOAc/hexanes) to yield colorless 
oil (0.7225 g, 86%): 1H NMR (CDCl3, 500 MHz) δ 7.48 – 7.20 (m, 5H, ArH), 3.64 (d, J = 6.5 Hz, 
2H, OCH2), 1.36 (s, 6H, 2 x CH3). 
 
2-Methyl-2-phenylpropanol (45) 
This known compound was prepared according to a modified procedure from 
Zaysev et al.44  Pyridinium chlorochromate (1.44 g, 6.66 mmol), sodium acetate 
(0.08 g, 1.00 mmol), and silica (1.03 g, 16.65 mmol) were suspended in CH2Cl2 (60 mL) and 
stirred at rt for 5 min.  Alcohol 44 (0.50 g, 3.33 mmol) in CH2Cl2 (6 mL) was added dropwise to 
reaction flask and stirred for 2 h at rt.  The reaction mixture was filtered through a silica pad and 
washed with CH2Cl2 (3 x 20 mL).  The filtrate was concentrated in vacuo and purified by column 
chromatography (SiO2, 5 % EtOAc/hexanes) to yield colorless oil (0.3251 g, 69%): 
1H NMR 





This known compound was prepared according to a modified procedure from 
Morrill et al.46  In the reaction flask, methyltriphenylphosphonium bromide (0.97 g, 
2.70 mmol) was suspended in dry benzene (8 mL) and stirred at rt for 5 min.  NaHMDS (1 M in 
hexanes, 2.60 mL, 2.60 mmol) was added dropwise and the mixture stirred for 5 min at rt.  
Aldehyde 45 (0.18 g, 1.23 mmol) in benzene (2 mL) was added dropwise and the reaction flask 
was heated to 60 οC for 16 h.  The reaction mixture was cooled to rt, then diluted with water (8 
mL) and the resulting layers separated.  The aqueous layer was extracted with EtOAc (3 x 10 mL), 
and the combined organic layers were dried with MgSO4 then concentrated in vacuo.  The sample 
was purified by column chromatography (SiO2, 10 % EtOAc/hexanes) to yield colorless oil 
(0.0737 g, 41%): 1H NMR (CDCl3, 500 MHz) δ 7.40 –7.19 (m, 5H, ArH), 6.06 (ddd, J = 17.3, 
10.6, 0.5 Hz, 1H, vinyl CH), 5.11 – 5.00 (m, 2H, =CH2), 1.43 (d, J = 0.5 Hz, 6H, 2 x CH3). 
 
1-Acetyl-4-methyl-3-phenyl-4-vinyl-1,3-diazetidin-2-one (47) 
This compound was prepared according to a modified procedure from Morrill et 
al.46  Methyltriphenylphosphonium bromide (1.67 g, 3.29 mmol) was suspended 
in dry benzene (15 mL) and stirred at rt for 5 min.  NaHMDS (1 M in THF, 3.10 
mL, 3.10 mmol) was added dropwise and the reaction flask was stirred for 5 min at rt.  Aldehyde 
8 (0.38 g, 1.63 mmol) in benzene (5 mL) was added dropwise to the reaction flask and then heated 
to 60 οC for 16 h.  The reaction mixture was cooled to rt, then diluted with water (15 mL) and the 
resulting layers separated.  The aqueous layer was extracted with EtOAc (3 x 15 mL), and the 
combined organic layers were dried with MgSO4 then concentrated in vacuo.  The sample was 
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purified by column chromatography (SiO2, 10 % EtOAc/hexanes) to yield yellow solid (0.1448 g, 
39%): 1H NMR (CDCl3, 500 MHz) δ 7.37 – 7.10 (m, 5H, ArH), 6.11 (dd, J = 17.4, 10.7 Hz, 1H, 
=CH2), 5.72 (d, J = 17.3 Hz, 1H, vinyl CH), 5.60 (d, J = 10.7 Hz, 1H, =CH2), 2.40 (s, 3H, COCH3), 
2.03 (s, 3H, CH3); 
13C NMR (CDCl3, 126 MHz) δ 165.61, 155.04, 146.24, 135.78, 134.69, 129.36, 




This compound was prepared according to a modified procedure from Morrill 
et al.46  Alkene 47 (0.10 g, 0.46 mmol) in dry THF (4 mL) was cooled to 0 οC, 
then borane tetrahydrofuran complex (1 M in THF, 0.92 mL, 0.92 mmol) was 
added dropwise.  The reaction flask was warm to rt and stirred for 1 h, then a second portion of 
BH3·THF (1 M in THF, 0.50 mL, 0.50 mmol) was added and stirred for additional 30 min at rt.  
The reaction mixture was cooled to 0 οC, then in a dropwise manner a NaOH solution (1 M, 4 mL) 
was added which was immediately followed by the addition of H2O2 solution (30%, 4 mL) and the 
reaction mixture was warmed to rt and stirred for 1 h.  The reaction mixture was diluted with brine 
(10 mL) and the resulting layers were separated.  The aqueous layer was extracted with EtOAc (3 
x 10 mL), and the combined organic layers were dried with MgSO4 and concentrated in vacuo.  
The sample was purified by column chromatography (SiO2, 20 % EtOAc/hexanes) to yield yellow 
oil (0.0317 g, 29%): 1H NMR (CDCl3, 500 MHz) δ 7.31 –7.15 (m, 5H, ArH), 6.98 (tt, J = 7.1, 1.2 
Hz, 1H, NCH2), 3.78 – 3.62 (m, 2H, OCH2), 3.36 – 3.13 (m, 2H, CH2), 2.32 – 2.13 (m, 3H), 1.66 
(s, 3H, CH3), 1.25 (t, J = 7.3 Hz, 4H, NCH2CH3); 
13C NMR (CDCl3, 101 MHz) δ 153.93, 137.71, 
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129.34, 122.34, 115.77, 79.68, 57.90, 38.29, 35.19, 22.92, 14.91; HRMS (ES+) calcd for 




This known compound was prepared according to the procedure from 
Hayakawa et al.64  To the reaction flask, N-diisopropylamine (7.09 mL, 
5.12 g, 50.60 mmol) was dissolved in dry THF (50 mL) and then cooled to -78 οC.  n-BuLi (1.6 M 
in THF, 48.7 mL, 63.25 mmol) was added dropwise and stirred at -78 oC for 5 min.  Ethyl 
acetoacetate (3.22 mL, 3.29 g, 25.30 mmol) in THF (20 mL) was added dropwise to the reaction 
flask, then stirred at 0 oC for 30 min.  Propargyl bromide (80 % in toluene, 3.10 g, 25.30 mmol) 
was added in one portion to the reaction flask and stirred at 0 oC for 1 h.  The reaction was quenched 
with a sat. NH4Cl solution (4 mL), then diluted with water (50 mL) and Et2O (50 mL).  The 
resulting layers were separated, and the aqueous layer extracted with Et2O (2 x 25 mL).  The 
combined organic layers were washed with brine (50 mL) and dried with MgSO4, then 
concentrated in vacuo.  The sample was purified by column chromatography (SiO2, 10 % 
EtOAc/hexanes) to yield colorless oil (2.8212 g, 66%): 1H NMR (CDCl3, 400 MHz) δ 4.21 (q, 2H, 
OCH2), 3.46 (s, 2H, CH2), 2.82 (t, 2H, CH2), 2.47 (m, 2H, CH2), 1.96 (s, 1H, CH), 1.28 (t, 3H, 
OCH2CH3).   
 
Ethyl-2-(2-(3-butynyl)-1,3-dioxolan-2-yl)acetate (53) 
This known compound was prepared according to the procedure from 
Hayakawa et al.64  Alkyne 52 (2.17 g, 12.90 mmol) was dissolved in benzene 
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(40 mL) and stirred at rt for 5 min.  Ethylene glycol (2.17 mL, 2.41 g, 38.70 mmol) was added to 
the reaction flask followed by p-toluenesulfonic acid (0.25 g, 1.30 mmol) and the mixture was 
heated to reflux with a dean-stark trap for 16 h.  The reaction was cooled to rt, then poured over a 
sat. NaHCO3 solution (40 mL) and ice.  The resulting layers were separated, and the aqueous layer 
was extracted with EtOAc (3 x 20 mL).  The combined organic layers were washed with brine (20 
mL), dried with MgSO4 then concentrated in vacuo.  The sample was purified by column 
chromatography (SiO2, 20 % EtOAc/hexanes) to yield faint yellow oil (2.1101 g, 77%): 
1H NMR 
(CDCl3, 400 MHz,) δ 4.21 (q, 2H, OCH2), 4.01 (s, 4H, OCH2CH2O), 3.46 (s,2H, CH2), 2.82 (t, 
2H, CH2), 2.47 (m, 2H, CH2), 1.96 (s, 1H, CH), 1.28 (t, 3H, OCH2 CH3). 
 
2-(3-butynyl)-2-(2-hydroxyethyl)-1,3-dioxolane (54) 
This known compound was prepared according to the procedure from 
Hayakawa et al.64  LiAlH4 (0.38 g, 10.10 mmol) was suspended in dry THF 
(35 mL) and cooled to -78 oC.  Protected ester 53 (2.13 g 10.10 mmol) in THF (5 mL) was added 
dropwise to the reaction flask.  The reaction mixture was warm to rt and stirred for 3 h.  The 
reaction mixture was quenched with a 15% NaOH solution (10 mL), then filtered through a celite 
plug.  The filtrate was extracted with EtOAc (3 x 20 mL) and the combined organic layers were 
dried with MgSO4 then concentrated in vacuo.  The sample was purified by column 
chromatography (SiO2, 50 % EtOAc/hexanes) to yield a colorless oil (1.4512 g, 86%): 
1H NMR 
(CDCl3, 400 MHz,) δ 4.01 (m, 4H, OCH2CH2O), 3.76 (q, 2H, CH2), 2.66 (t, 1H, CH2), 2.28 (m, 






This known compound was prepared according to the procedure from 
Hayakawa et al.64  Alcohol 54 (1.36g, 8.00 mmol) was dissolved in acetone 
(25 mL) and stirred at rt for 5 min.  p-Toluenesulfonic acid (0.38 g, 2.00 mmol) was added and the 
reaction flask was stirred at rt for 2 h.  The reaction mixture was poured over a sat. NaHCO3 
solution (20 mL) and ice, and the resulting layers were separated. The aqueous layer was extracted 
with Et2O (3 x 20 mL), and the combined organic layers were washed with brine (20 mL), dried 
with MgSO4, then concentrated in vacuo.  The sample was purified by column chromatography 
(SiO2, 80 % EtOAc/hexanes) to yield a colorless oil (0.6834 g, 67%): 
1H NMR (CDCl3, 400 MHz,) 
δ 3.87 (t, 2H, OCH2), 2.71 (t, 4H, 2 x CH2), 2.48 (m, 2H, CH2), 2.38 (br, 1H, OH), 1.97 (t, 1H, 
CH).   
 
2-(3-(But-3-yn-1-yl)-3H-diazirin-3-yl)ethanol (56) 
This known compound was prepared according to the procedure form 
Hayakawa et al.64  With the use of a cold finger trap, anhydrous ammonia (35 
mL) was condensed into reaction flask containing ketone 55 (4.43 g, 35.00 mmol).  The reaction 
flask was then heated to 40 oC and stirred for 5 h maintaining cold finger trap at -78 οC.  
Hydroxylamine-O-sulfonic acid (4.55 g, 40.25 mmol) in methanol (35 mL) was added dropwise 
to the reaction flask, then continued to be heated at 40 oC for 1 h.  The cold finger trap was slowly 
warm to rt and the ammonia was allowed to evaporate overnight.  The resulting white solid was 
filtered through a silica plug and washed with methanol (3 x 25 mL), then condensed in vacuo.  
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The mixture was dissolved in CH2Cl2 (17 mL) and triethylamine (6.13 mL, 4.45 g, 43.98 mmol) 
was added to the reaction flask, and stirred for 30 min at rt.  An iodine solution (8 g, 50.4 mmol in 
18 mL CH2Cl2) was added dropwise to the reaction flask until an orange/brown color persisted, 
and the resulting solution was concentrated in vacuo.  The sample was purified excluding light by 
column chromatography (SiO2, 80 % CH2Cl2/hexanes) to yield a faint yellow oil (2.02 g, 43%): 
1H NMR (CDCl3, 400 MHz,) δ 3.51 (t, 2H, ICH2), 2.07 (m, 3H, CH2 and CH), 1.70 (m, 5H, 2 x 
CH2 and OH). 
 
3-(but-3-yn-1-yl)-3-(2-iodoethyl)-3H-diazirine (49) 
This known compound was prepared according to the procedure from 
Hayakawa et al.64  Iodine (1.11 g, 4.40 mmol), triphenylphosphine (1.05 g, 4.00 
mmol), and imidazole (0.74 g, 10.90 mmol) were dissolved in CH2Cl2 (20 mL) and the reaction 
flask was cooled to 0 oC.  Excluding light, diazirine 56 (0.50 g, 3.60 mmol) in CH2Cl2 (4 mL) was 
slowly added to reaction flask and stirred for 4 h at 0 oC.  The reaction mixture was quenched with 
a sat. Na2S2O3 solution (20 mL) and the resulting layers were separated.  The aqueous layer was 
extracted with EtOAc (3 x 25 mL), and the combined organic layers were washed with brine (30 
mL), dried with MgSO4, then concentrated in vacuo.  The sample was purified excluding light by 
column chromatography (SiO2, 8 % EtOAc/hexanes) to yield a yellow oil (0.3822 g, 42%): 
1H 
NMR (CDCl3, 400 MHz,) δ 2.89 (t, 2H, CH2), 2.12 (t, 2H, CH2), 2.01 (m, 3H, CH2 and CH), 1.69 
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